Natural killer (NK) cells play an important role in the detection and killing of stressed cells, including those of a cancerous origin. This process is done via initiation of antibody-dependent cellular cytotoxicity (ADCC). FcγRIIIa, also known as CD16a, is expressed on the surface of these NK cells and is a vital receptor in the activation of ADCC. Therefore, this receptor has been used as a target in cancer drug development. Current research should focus more on the activation of Fc?RIIIa or inhibition of factors that downregulate CD16a, most notably ADAM17 and PTEN. While monoclonal antibody therapy is widely used, inhibition of these cancer immuneditors, which results in higher levels of ADCC, has not yet reached the spotlight. Thus, ADAM17 and PTEN inhibitors should be further researched to uncover their full potential.